Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, Klare P, Link T, Rhiem K, Bayer C, Reinisch M, Bjelic-Radisic V, Zahm DM, Hanusch C, Solbach C, Heinrich G, Hartkopf AD, Schneeweiss A, Fasching P, Filmann N, Nekljudova V, Holtschmidt J, Stickeler E, Loibl S.
Meyer-Wilmes P, et al. Among authors: heinrich g.
ESMO Open. 2024 May;9(5):103009. doi: 10.1016/j.esmoop.2024.103009. Epub 2024 Apr 24.
ESMO Open. 2024.
PMID: 38663168
Free PMC article.
Clinical Trial.